Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770795 | 0.88 | AGTR1 (0.51) | AGTR1AGTR2EDNRA | |
| SCHEMBL4769386 | 0.87 | EDNRA (0.58) | EDNRA | |
| SCHEMBL4771492 | 0.87 | AGTR1 (0.51) | AGTR1AGTR2EDNRA | |
| SCHEMBL4764100 | 0.83 | AGTR1 (0.51) | AGTR1AGTR2 | |
| SCHEMBL4764548 | 0.81 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL4764431 | 0.81 | AGTR1 (0.61) | AGTR1AGTR2 | |
| SCHEMBL4793147 | 0.81 | EDNRA (0.44) | AGTR1AGTR2EDNRA | |
| SCHEMBL4764624 | 0.81 | EDNRA (0.59) | EDNRA | |
| SCHEMBL27542919 | 0.79 | AGTR1 (0.46) | AGTR1AGTR2EDNRA | |
| SCHEMBL27571317 | 0.79 | EDNRA (0.52) | EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-07-01 | — | — | US | claimed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | claimed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127515-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885AGTR2 2/4885TSHR 238/4885 |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885AGTR2 2/4885TSHR 238/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | AGTR1 4/4885AGTR2 2/4885TSHR 238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.